Together, our study reveals that the TRPML1 agonist ML-SA1 reverses multiple key EAL abnormalities in primary neurons caused by PIKfyve inhibition that are similar to those described in AD neurons. This evidence concerns the gene MCOLN1 and Alzheimer disease.